Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brentuximab vedotin–based PET-adapted therapy in pediatric and AYA Hodgkin lymphoma
jRCTs041250148Recruiting
- Sponsor
- Japan Agency for Medical Research and Development
- Start
- Dec 2025
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Open-label trial of brentuximab vedotin in Hodgkin lymphoma (HL) (3 arms), sponsored by Japan Agency for Medical Research and Development. Primary endpoint: Percentage of Complete Remission at the End of Treatment. Started Dec 2025; status: recruiting.
02
Drugs
brentuximab vedotin
03
Conditions
Hodgkin lymphoma (HL)
Beyond the preview
Go deeper on jRCTs041250148.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs041250148.